Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

NCT07486648 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)
Lung Cancer (Non-Small Cell)
Advanced Non-small-cell Lung Cancer

Interventions

DRUG: Capivasertib in combination with Osimertinib

Sponsor

Shanxi Province Cancer Hospital

Collaborators

[object Object]